Incidence and Risk Factors for Gadolinium-Based Contrast Agent Immediate Reactions.

AbstractSince their clinical introduction in 1988, gadolinium-based contrast agents (GBCAs) have demonstrated an excellent safety profile with a reported acute adverse reaction rate ranging from 0.01% to 2%. By comparison, the acute adverse reaction rate of low osmolar nonionic computed tomography c